Non-alcoholic fatty liver disease: pathogenesis and models
- 1 January 2024
- journal article
- review article
- Vol. 16 (2) , 387-399
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a complex disease characterized by a massive accumulation of lipids in the liver, with a continuous progression of simple steatosis, non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. Non-alcoholic fatty liver disease is associated with obesity, insulin resistance, and metabolic syndrome; it is a severe public health risk and is currently the most common liver disease of the world. In addition to the fatty infiltration of the liver in non-alcoholic fatty liver disease patients, the field of liver transplantation faces similar obstacles. NAFLD and NASH primarily involve lipotoxicity, inflammation, oxidative stress, and insulin resistance. However, the precise mechanisms and treatments remain unclear. Therapeutic approaches encompass exercise, weight control, as well as treatments targeting antioxidants and anti-inflammatory pathways. The role of animal models in research has become crucial as a key tool to explore the molecular mechanisms and potential treatments for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Here, we summarized the current understanding of the pathogenesis of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis and discussed animal models commonly used in recent years.Keywords
This publication has 72 references indexed in Scilit:
- Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontinAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2004
- Hepatocyte Apoptosis, Expression of Death Receptors, and Activation of NF-κB in the Liver of Nonalcoholic and Alcoholic Steatohepatitis PatientsAmerican Journal of Gastroenterology, 2004
- Approach to the Pathogenesis and Treatment of Nonalcoholic SteatohepatitisDiabetes Care, 2004
- Model of nonalcoholic steatohepatitisThe American Journal of Clinical Nutrition, 2004
- Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectinGastroenterology, 2003
- Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitisJournal of Hepatology, 2003
- Leptin is essential for the hepatic fibrogenic response to chronic liver injuryJournal of Hepatology, 2002
- Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscleJournal of Applied Physiology, 2002
- Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic isletsProceedings of the National Academy of Sciences, 2000
- Steatohepatitis: A tale of two “hits”?Gastroenterology, 1998